SalaryGuide
AboutPricingFor Employers

Marketing jobs

1 marketing jobs

Apellis Pharmaceuticals logo
4 hrs ago

Senior Product Manager, Patient Marketing

Apellis Pharmaceuticals

Waltham, MA (Hybrid)Full time$147K/yr – $196K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
Apellis Pharmaceuticals logo

Senior Product Manager, Patient Marketing

Apellis Pharmaceuticals

Waltham, MA (Hybrid)

$147K/yr - $196K/yrIn-houseFull-timeSenior level5+ years exp.
4 hrs ago
Apellis Pharmaceuticals logo
Apellis Pharmaceuticals

Senior Product Manager, Patient Marketing

Waltham, MA (Hybrid)

$147K/yr – $196K/yrSenior Level5+ years expFull time

Posted 4 hrs ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the US marketing vision and multi-channel execution, leading cross-functional programs from patient initiatives to agency management and budget stewardship.

  • Lead multi-year strategy, stakeholder engagement, and budget development
  • Develop and execute measurement plans and field strategies with sales, training, and patient services

Job Description

Responsibilities

  • Lead the development of personal and non-personal tactics, including but not limited to patient programs, co-development of content with patient ambassadors, live events on social media, social media content, digital assets, media planning and print.
  • Playing a key role in driving US Brand Planning – inclusive of defining stakeholder strategies - and budget development
  • Helping define and execute the vision and plan for US marketing. Manage multiple agencies in the execution of that plan.
  • Developing field execution strategy for patient-facing initiatives in partnership with training and sales leadership and patient services leadership
  • Developing a multi-channel/digital strategy and measurement plan
  • Develop the overall tactical measurement plan and develop courses of action based on these metrics
  • Supporting POA strategy and execution
  • Efficiently and thoughtfully administering the US marketing budget
  • Working closely with regulatory, legal, and compliance

Requirements

  • Bachelor's degree required
  • 5+ years of biotech/pharma marketing experience
  • Eye care experience a plus
  • Experience in sales or customer-facing roles
  • Willing to travel domestically up to 30% of the time and attend events outside of business hours (e.g., occasional weekends and evenings)
  • Proficiency or comfort with high science data and demonstrated ability to convert into promotional messaging
  • Ability to navigate and be successful in a fast-paced, results-driven environment, managing through ambiguity
  • Commitment to collaboration and engagement, with a history of success leading in a matrix environment and with agency partners
  • An entrepreneurial spirit coupled with the drive to embrace innovation and develop creative but well-reasoned solutions to business challenges
  • Demonstrated integrity on the job, including an understanding of relevant rules and regulations

Benefits

  • 401(k) plan with company match
  • inclusive family building benefits
  • flexible time off
  • summer and winter shutdowns
  • paid family leave
  • disability and life insurance
  • and more
Apellis Pharmaceuticals logo

Apellis Pharmaceuticals

3.2 Glassdoor

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8

Founded in 2008
Waltham, Massachusetts, USA
796 employees (44 in marketing)
apellis.com
59% recommend to a friend
71% CEO approval

Traffic Signals

Monthly Visitors
27.9K
Traffic Source Mix
Search
41.6%
Direct
46.1%
Referral
6.4%
Social
4.5%
Paid
1.3%

Headcount Trend

Current headcount: ~810

Marketing Team

Marketing Team Size
39 (5% of company)
Median Tenure
3 years
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$919.6M
Last Raise
$275M
Post IPO Debt, 10 months ago

Funding History

  • Jun 2025
    Post IPO Debt • $275M
  • May 2024
    Post IPO Debt • $475M
  • Apr 2022
    Post IPO Equity • $1.1M

Recent News

Will a bounce in Apellis Pharmaceuticals Inc. offer an exit - 2025 Bull vs Bear & Reliable Price Breakout Signals
Nov 19, 2025 • newser.com
Using AI based signals to follow Apellis Pharmaceuticals Inc. - 2025 Price Momentum & Verified Trade Idea Suggestions
Nov 19, 2025 • newser.com
Apellis Pharmaceuticals (BIT:1APLS) Price Target Decreased by 10.35% to 30.35
Nov 16, 2025 • Nasdaq
Will breakout in Apellis Pharmaceuticals Inc. lead to full recovery - 2025 Short Interest & Real-Time Volume Triggers
Nov 16, 2025 • newser.com
Is Five-Year SYFOVRE Data Shifting the Investment Case for Apellis Pharmaceuticals (APLS)?
Nov 13, 2025 • Yahoo Finance
What's Going On With Apellis Pharma Stock Wednesday? - Apellis Pharmaceuticals (NASDAQ:APLS)
Nov 12, 2025 • Benzinga
Apellis Pharmaceuticals Inc. recovery potential after sell off - July 2025 News Drivers & Real-Time Buy Signal Alerts
Nov 10, 2025 • newser.com
Mizuho lowers Apellis Pharmaceuticals stock price target on Syfovre growth challenges
Nov 3, 2025 • Investing.com
Why Apellis Pharmaceuticals Shares Are Under Pressure
Nov 3, 2025 • TipRanks
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2025 Earnings Call Transcript
Nov 1, 2025 • Insider Monkey
Apellis Pharmaceuticals (APLS): Forecast 13% Annual Revenue Growth, Shares Trade at Deep Discount Heading Into Earnings
Oct 31, 2025 • Yahoo Finance
Apellis Pharmaceuticals (APLS): Discounted Valuation Reinforces Bullish Narrative Ahead of Profitability Targets
Oct 31, 2025 • simplywall.st
Apellis Pharmaceuticals (APLS): Discounted Valuation Reinforces Bullish Narrative Ahead of Profitability Targets
Oct 31, 2025 • Sahm
Apellis (Nasdaq: APLS) receives $275M from Sobi royalty deal, revenue totals $459M
Oct 30, 2025 • Stock Titan
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
Oct 30, 2025 • Yahoo Finance
Apellis Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Oct 30, 2025 • TradingView
Apellis Pharmaceuticals Reports Strong Q3 2025 Earnings
Oct 30, 2025 • TipRanks
Earnings call transcript: Apellis Pharmaceuticals Q3 2025 earnings beat expectations but stock tumbles
Oct 30, 2025 • Investing.com
Earnings To Watch: Apellis Pharmaceuticals Inc (APLS) Reports Q3 2025 Result
Oct 29, 2025 • Yahoo Finance
Why Apellis Pharmaceuticals Shares Are On The Move
Oct 29, 2025 • TipRanks
Apellis Pharmaceuticals Advances APL2 Study for Rare Kidney Disease
Oct 27, 2025 • TipRanks
Why Apellis Pharmaceuticals (APLS) Could Gain from EMPAVELI’s Edge in Rare Kidney Disease Treatment
Oct 24, 2025 • Yahoo Finance
Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth
Oct 23, 2025 • Yahoo Finance
Can Apellis Pharmaceuticals Inc. (1JK) stock survive global slowdown - July 2025 Summary & Technical Pattern Based Buy Signals
Oct 23, 2025 • newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic value - Rate Cut & Fast Exit and Entry Trade Guides
Oct 21, 2025 • newser.com
Price momentum metrics for Apellis Pharmaceuticals Inc. explained - 2025 Market Overview & Fast Moving Market Watchlists
Oct 21, 2025 • newser.com
How to integrate Apellis Pharmaceuticals Inc. into portfolio analysis tools - 2025 AllTime Highs & Daily Profit Focused Screening
Oct 21, 2025 • newser.com
Can Apellis Pharmaceuticals Inc. (1JK) stock survive global slowdown - Layoff News & Verified Short-Term Plans
Oct 21, 2025 • newser.com
Apellis Pharmaceuticals (APLS): Assessing Valuation Following Wells Fargo’s Upgrade and Renewed Analyst Confidence
Oct 20, 2025 • simplywall.st
Hold Rating for Apellis Pharmaceuticals Amid Limited Growth Potential and Market Challenges
Oct 20, 2025 • TipRanks
BofA Securities raises Apellis Pharmaceuticals stock price target to $29
Oct 20, 2025 • Investing.com
Did Rising Analyst Upgrades and Strong Consensus Just Shift Apellis Pharmaceuticals' (APLS) Investment Narrative?
Oct 18, 2025 • Sahm
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
Oct 16, 2025 • Yahoo Finance
Oct. 30 conference call: Apellis will discuss Q3 2025 financial results; webcast replay available 90 days
Oct 16, 2025 • Stock Titan
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 11 Analysts
Oct 15, 2025 • Benzinga
Apellis Pharmaceuticals Shares Rise After Wells Fargo Upgrade
Oct 15, 2025 • MarketScreener
Apellis Pharma director Dunlop A. Sinclair sells $737k in APLS
Oct 15, 2025 • Investing.com
Wells Fargo Upgrades Apellis Pharmaceuticals (APLS) to Overweigh
Oct 15, 2025 • GuruFocus
Earnings call transcript: Apellis Pharmaceuticals Q2 2025 reveals revenue growth
Oct 14, 2025 • Investing.com
IBD Rating Upgrades: Apellis Pharmaceuticals Shows Improved Technical Strength
Oct 13, 2025 • Investor's Business Daily
Stevenson Search Partners Recruits Chief Research and Development Officer for Apellis Pharmaceuticals
Oct 10, 2025 • Hunt Scanlon Media
Assessing Apellis Pharmaceuticals (APLS) Valuation Following Recent Share Price Uptick
Oct 3, 2025 • simplywall.st
Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS)
Sep 30, 2025 • Insider Monkey
Apellis Pharmaceuticals: Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders
Sep 30, 2025 • Seeking Alpha
Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS)
Sep 30, 2025 • Yahoo Finance
H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock
Sep 29, 2025 • Investing.com
Apellis stock cut to sell at Goldman Sachs (APLS:NASDAQ)
Sep 26, 2025 • Seeking Alpha
Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Sep 26, 2025 • Benzinga.com
Intel, Johnson & Johnson and Boeing rise premarket; Wayfair falls
Sep 26, 2025 • Investing.com
Spherix Global Insights Highlights Patient Influence in Shaping PNH Treatment Choices
Sep 26, 2025 • Spherix Global Insights
Apellis Pharma VP Chopas sells $4.5k in shares
Sep 17, 2025 • Investing.com
When Can We Expect A Profit From Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)?
Sep 12, 2025 • Yahoo Finance
Apellis Pharmaceuticals Insider Sold Shares Worth $1,190,130, According to a Recent SEC Filing
Sep 10, 2025 • MarketScreener
Apellis Pharmaceuticals at Baird Conference: Strategic Insights in Healthcare
Sep 9, 2025 • Investing.com
eGenesis Secures IND Clearance for EGEN-2784 in Kidney Transplant and Reports Significant Patient Progress
Sep 9, 2025 • synbiobeta.com
Is Apellis Set for a Rebound?
Sep 2, 2025 • timothysykes.com
Apellis Pharmaceuticals Insider Sold Shares Worth $6,352,743, According to a Recent SEC Filing
Aug 29, 2025 • MarketScreener
Apellis Pharmaceuticals to Participate in Upcoming September 2025 Investor Conferences
Aug 28, 2025 • BioSpace
Biotech Leader Apellis Pharmaceuticals Announces Triple Conference Schedule for September 2025
Aug 27, 2025 • Stock Titan
Stocks To Watch: Apellis Pharmaceuticals Sees Relative Strength Rating Rise To 81
Aug 27, 2025 • Investor's Business Daily
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 27, 2025 • Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 27, 2025 • MarketScreener
Earnings call transcript: Apellis Pharmaceuticals Q2 2025 beats EPS forecast, stock surges
Aug 21, 2025 • Investing.com
Critical Inflection Point in FSGS on the Horizon with Nephrologists Poised to Rapidly Adopt New Therapies, According to Spherix Global Insights
Aug 21, 2025 • Spherix Global Insights
Age-Related Macular Degeneration Market Set to Reach $15.4 Billion by 2032
Aug 19, 2025 • EIN Presswire
FDA approves Apellis’ Empaveli for two rare kidney diseases
Aug 18, 2025 • PMLiVE
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli’s New Approval (APLS)
Aug 14, 2025 • Seeking Alpha
FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week
Aug 13, 2025 • Insider Monkey
FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week
Aug 12, 2025 • Yahoo Finance
Apellis Pharmaceuticals’ Earnings Call: A Balanced Outlook
Aug 5, 2025 • TipRanks
FDA approves Empaveli for rare kidney diseases
Aug 4, 2025 • Medical Xpress - latest medical and health news stories
Apellis Pharmaceuticals Inc (APLS) Q2 2025 Earnings Call Highlig
Aug 1, 2025 • GuruFocus
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target
Aug 1, 2025 • Yahoo Finance
Apellis Pharmaceuticals: The Picture Becomes Clearer (NASDAQ:APLS)
Aug 1, 2025 • Seeking Alpha
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
Jul 31, 2025 • Yahoo Finance
FDA Approves Apellis’ Empaveli for C3 Glomerulopathy, Primary Immune Complex Membranoproliferative Glomerulonephritis
Jul 31, 2025 • Pharmaceutical Executive
Apellis Pharmaceuticals Reports Q2 2025 Financial Results and Announces FDA Approval of EMPAVELI for C3 Glomerulopathy and Primary IC-MPGN | APLS Stock News
Jul 31, 2025 • Quiver Quantitative
Apellis Pharmaceuticals Reports Q2 2025 Earnings
Jul 31, 2025 • TipRanks
Apellis Scores Major FDA Approval for EMPAVELI, Secures $300M Deal and Reports Strong Q2 Earnings
Jul 31, 2025 • Stock Titan
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
Jul 31, 2025 • BioSpace
Apellis Pharmaceuticals GAAP EPS of -$0.33 beats by $0.15, revenue of $178.5M misses by $10.15M
Jul 31, 2025 • Seeking Alpha
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
Jul 31, 2025 • Apellis Pharmaceuticals, Inc.
Scotiabank raises Apellis Pharmaceuticals stock price target on FDA approval
Jul 30, 2025 • Investing.com
What To Expect From Apellis Pharmaceuticals Inc (APLS) Q2 2025 Earnings
Jul 30, 2025 • Yahoo Finance
Apellis wins US approval for Empaveli in rare kidney diseases
Jul 30, 2025 • The Pharma Letter
Apellis' Empaveli gains FDA nod for broader C3 glomerulopathy use, rivalling Novartis' Fabhalta
Jul 29, 2025 • FirstWord Pharma
Cantor Fitzgerald reiterates Overweight rating on Apellis stock after FDA approval
Jul 29, 2025 • Investing.com
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Jul 29, 2025 • BioSpace
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio
Jul 29, 2025 • Benzinga.com
Apellis Pharmaceuticals Says Kidney Disease Treatment Wins FDA Approval
Jul 29, 2025 • MarketScreener
Apellis’ Empaveli approved in US for two rare kidney diseases
Jul 29, 2025 • BioWorld Financial Watch
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the
Jul 28, 2025 • GlobeNewswire
Trading Halted for Apellis Pharmaceuticals (APLS) Amid Pending A
Jul 28, 2025 • GuruFocus
FDA Approves First Treatment for Rare Kidney Disease C3G, Shows 68% Efficacy | APLS Stock News
Jul 28, 2025 • Stock Titan
Apellis counters Novartis with broad label for Empaveli in kidney disease
Jul 28, 2025 • Fierce Pharma
Apellis Pharmaceuticals Gets FDA Approval for Kidney Disease Treatment
Jul 28, 2025 • Morningstar.com
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
Jul 24, 2025 • Yahoo Finance
Apellis Pharmaceuticals to Host Conference Call for Q2 2025 Financial Results on July 31 | APLS Stock News
Jul 24, 2025 • Quiver Quantitative
Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Raises Target Price to $50
Jul 18, 2025 • 富途牛牛
Apellis stock holds Outperform rating at William Blair amid Izervay competition
Jul 10, 2025 • Investing.com